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Purpose or Objective: To compare patterns of acute and 
late clinical/radiological lung toxicity following either 3D or 
image-guided VMAT stereotactic radiotherapy for stage I non-
small cell lung cancer (NSCLC). 
 
Material and Methods: In this observational study, we 
included 148 patients from a prospective mono-institutional 
SBRT series (time interval 2004-2014). All subjects had 
peripheral tumors and a prescription BED10Gy (at 80%) in the 
range 100-120 Gy. The first 95 patients (2004-2010) were 
planned with 3D-CRT, using multiple non-coplanar fields; a 
stereotactic body frame was used with CTV-PTV margins of 5 
mm (antero-posterior and latero-lateral) and 10 mm (cranio-
caudal). The second cohort (2010-2014) included 53 patients, 
planned with volumetric IMRT, using a single/multi arcs VMAT 
technique, on a PTV generated with 3 mm margins from a 
patient’s specific ITV (obtained from 4D-CT), with a 
frameless approach through cone-beam CT guidance. Clinical 
acute and late toxicities were scored according to RTOG 
scales; radiological acute (<6 months from SBRT) and late (>6 
months post SBRT) toxicity on the basis of modified Kimura 
and Koenig’s classifications, respectively. Student’s T test 
was used to compare clinical characteristics, and Pearson’s 
chi square test to compare the incidence of any grade lung 
toxicity. 
 
Results: Patients and tumors’ characteristics were similar 
and well matched between the groups. PTV volumes were 
also comparable (35.1 cc for 3D-CRT vs. 40.3 cc for VMAT,, 
p=0.16). Moreover, no significant difference was detected in 
Mean Lung Dose, converted in 2 Gy equivalent (11.7 vs. 10.4 
Gy for 3D-CRT and VMAT, respectively, p=0.13). Frequencies 
of acute and late clinical toxicity (all grades) were 
superimposable between 3D-CRT and VMAT (acute: 10.5% vs. 
22.6%, p=0.28; late: 4.2% vs. 13%, p=0.09, respectively). The 
crude rate of RTOG acute ≥ grade 3 radiation pneumon itis 
was 2.1% after 3D-CRT and 3.8% after VMAT. Acute and late 
radiological toxicity patterns were also similar between the 
two cohorts. Figures 1 and 2 depict the incidence and grade 
of both, according to different treatments. As expected, late 
radiological toxicity occurred in approximately 60% of 
patients, with modified conventional (25% after 3D-CRT vs. 
32.6% after VMAT) and mass-like (19.6% after 3D-CRT vs. 
17.4% after VMAT) patterns as the most commonly observed 
findings. 
 
 
 
 
Conclusion: Results of the present study indicate that the 
pattern of clinical and radiological toxicities following SBRT 
in peripheral early stage NSCLC treated with comparable 
BED10Gy is not influenced by the different techniques used 
for planning and delivery. 
 
EP-1229  
Non-small cell lung cancer: marked difference in first 
failure site depending on histology 
L. Nygaard
1The Finsen Center - Rigshospitalet, Department of 
Oncology- Section of Radiotherapy, Copenhagen, Denmark 
1, I. Vogelius1, K. Håkansson1, S. Langer2, G. 
Persson2, S. Bentzen3 
2The Finsen Center - Rigshospitalet, Department of 
Oncology, Copenhagen, Denmark 
3University of Maryland Greenebaum Cancer Center, Division 
of Biostatistics and Bioinformatics, Baltimore, USA 
 
Purpose or Objective: Inoperable non-small cell lung cancer 
(NSCLC) comprises several histological subtypes, with 
squamous cell carcinoma (SCC) and adenocarcinoma (AC) 
being most frequent. The prognosis is poor with current 
chemo-radiation strategies and treatment intensification is 
limited by patient tolerance. It is therefore relevant to target 
experimental therapeutic approaches to a patient's risk of 
local versus distant failure. The purpose of the current study 
was to compare the pattern of first relapse after chemo-
radiation for locally advanced pulmonary SCC and AC. 
 
Material and Methods: We retrospectively included 193 
patients with locally advanced NSCLC treated with chemo-
radiotherapy from 2009 to 2012. Patients with initial stage IV 
(n=17) disease and/or patients with histology other than AC 
or SCC (n=22) were excluded leaving 155 patient for the 
analysis. Patients were identified and grouped according to 
first event as either: loco-regional (LR) failure; intra-cranial 
distant metastases (ICDM), extra-cranial distant metastases 
(ECDM); dead without evidence of disease (Dead, NED), with 
the remaining patients being Alive, NED at latest follow-up in 
August 2015. The cumulative incidence of events was 
compared across the histology subtypes, using the competing 
risk method of Fine and Gray. 
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Results: Patients received sequential (n=49, 32%) or 
concomitant (n=93, 60%) chemo-radiotherapy. Eleven 
patients received radiotherapy alone.. Competing risks 
analysis found a significantly higher rate of ICDM in the AC 
group compared to SCC (p= 0.0004) but no significant 
difference in incidence of ECDM (p=0.08). LR failure was 
higher in SCC than in AC (p=0.01). There was no significant 
difference between the two histology groups in the 
proportion dying without evidence of disease (p=0.3), see 
Figure. Restricting the analysis to patients with distant 
metastases as first site of failure, there was a significantly 
higher rate of cerebral metastases in AC than in SCC (p= 
0.04), cf. Table 1. 
 
Conclusion: The pattern of first failure in inoperable NSCLC 
differs among patients with AC and SCC with intra-cranial 
distant metastases being more common in AC than in SCC and 
LR relapse being much more frequent in SCC than in AC. 
Experimental treatment strategies should be targeting 
different relapse patters in various histological subtypes. 
Intensification of local therapy for example may yield a 
worse risk/benefit ratio in AC compared to SCC.  
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Purpose or Objective: In addition to its curative use in early 
stage lung cancer, stereotactic ablative radiotherapy (SABR) 
can also potentially be indicated for pulmonary 
oligometastatic disease. This study aims to retrospectively 
analyze treatment outcomes and develop nomograms to 
predict survival. 
 
Material and Methods: From September 2012 to April 2015, 
treatment outcomes and toxicities for 85 cases of SABR in 72 
patients retrospectively reviewed. Prognostic factors were 
analyzed via multivariate analyses using Cox proportional 
hazards regression. Using factors that demonstrated to be 
significant in the Cox regression model, nomograms were 
constructed and validated internally. 
 
Results: After a median follow-up of 15 months, only 1 
patient showed local failure within the radiation field. The 
local failure-free survival (LFFS) rate at 2 years was 98%. The 
1-year and 2-year progression-free survival (PFS) and overall 
survival (OS) rates were 62% and 48%, and 90% and 72%, 
respectively. Multivariate analyses demonstrated that 
controlled primary cancer (p = 0.01), absence of 
extrapulmonary metastatic disease (p = 0.03), and disease-
free interval (DFI) longer than 1 year (p < 0.01) favorably 
affects PFS. Furthermore, the absence of extrapulmonary 
metastatic disease (p < 0.01) and lower performance status 
(p = 0.03) increased OS as well. In terms of internal 
validation, nomograms for PFS and OS revealed C-index of 
0.75 and 0.81, and showed a well-fitted calibration curves, 
respectively. Grade 1 or 2 radiation pneumonitis was found in 
37 cases, and grade 1 chest wall pain was found in 1 case. 
Any grade 3 or higher toxicities were not identified. 
 
 
 
 
Conclusion: SABR demonstrated good local control with 
tolerable adverse effects for pulmonary oligometastases. 
Several factors were predictive for survival. Based on these 
factors, nomograms presented in this study can potentially be 
a useful tool for the prediction of progression-free and 
overall survival rates. 
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